BioXcel Therapeutics, Inc. (BTAI) Q4 2024 Annual Earnings

BTAI·Reported March 27, 2025·Before market open

BioXcel Therapeutics, Inc. reported Q4 2024 revenue of $366.0K, missed analyst consensus of $718.3K by $352.3K. Diluted EPS came in at $-3.57, beat the $-4.36 consensus by $0.79.

Revenue

$366.0Kmissed by $352.3K

Consensus: $718.3K

Diluted EPS

$-3.57beat by $0.79

Consensus: $-4.36

SEC Filings

Earnings release8-K not filed yet

Annual report10-K · 0001558370-25-003985

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q4 2024 Earnings FAQ

Common questions about BioXcel Therapeutics, Inc.'s Q4 2024 earnings report.

BioXcel Therapeutics, Inc. (BTAI) reported Q4 2024 earnings on March 27, 2025 before market open.

BioXcel Therapeutics, Inc. reported revenue of $366.0K and diluted EPS of $-3.57 for Q4 2024.

Revenue missed the consensus estimate of $718.3K by $352.3K. EPS beat the consensus estimate of $-4.36 by $0.79.

You can read the 10-K periodic report (0001558370-25-003985) directly on SEC EDGAR. The filing index links above go to sec.gov.